This pharmaceutical firm had to bear with the wrath of the coronavirus pandemic. The main reason for this downfall was the locking down of the world for a specific amount of time to control the spread of the coronavirus. The virus, however, spread very quickly and affected a massive number of lives. The various sectors which had to suffer back then are now trying to recover from the losses they suffered at that time.

Bristol-Myers Squibb underwent losses because access to the hospitals and clinics was limited. Not all the patients could go to the hospitals because of the lockdowns or curfews and most importantly, the fear of the spread of the virus kept people away from the hospitals for some amount of time.

However, the year 2020 is not enough for the description of the performance of this firm because the company has had an overall better performance during the past times. It is also expected that the company will bounce back and perform well again in this year as well as the upcoming years.

Bristol-Myers Squibb Co. (NYSE: BMY)

  • 52 Week Range: $45.76 – $67.80
  • Average Volume: 10,731,482
  • Market Capital: $145.889B
  • Forward Dividend and Yield: 96 (3.05%)

Another plus point about the company is that its dividend has consistently increased for 11 years straight and there are no chances that it will stoop down so the investors can rely on the company for that matter. Moreover, the stocks are moderately priced and profitable giving so there is little risk except for the arrival of an unexpected situation like the pandemic in 2020.

An Investment in the Company Now: Safe or Not?

If we look back at the year 2020 and the performance of Bristol-Myers Squibb in that year then the investors might look upon the company as an investment with risk. On the other hand, if we consider the company based on its overall performance and the expected performance shortly, then the investors can get inclined towards buying this stock.

Some of the major drugs of the company such as Eliquis, Revlimid, Zeposia, Opdivoa, and Reblozyl are great sources of income for the company. The company is also in the process of developing and launching more drugs and this is something good because drugs and medicines are the main sources of revenue and profit for the firm.

The investors can go ahead and invest in the firm with the hope of some good profits to come in as expected. The pricing of the stock is quite reasonable and will suit the shareholders. The company has a stronghold in its field that will not subside because the company is growing and launching new products. There is always a risk involved when it comes to the stock market and the volatility of the stock market should always be kept in mind before investing. Hence, it is entirely dependent on the investors about the kind of investment they wish to make.

Leave a Reply

Your email address will not be published. Required fields are marked *